Swartz Robin 4
4 · Voyager Therapeutics, Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
Voyager Therapeutics (VYGR) COO Robin Swartz Sells 3,882 Shares
What Happened Robin Swartz, Voyager Therapeutics' COO and CBO, disposed of 3,882 shares of VYGR on Feb 18, 2026. The weighted-average price was $3.44 per share for total proceeds of approximately $13,354. The sale was reported on a Form 4 filed Feb 20, 2026.
Key Details
- Transaction type: Sale (code S) — 3,882 shares sold on 2026-02-18.
- Price: Weighted average $3.44; individual trade prices ranged $3.40–$3.47. (Footnote: reporting person can provide per-price breakdown on request.)
- Purpose: Footnote F1 states the sale was executed under a durable automatic sell-to-cover instruction (adopted May 12, 2025) to satisfy tax withholding for restricted stock units that vested Feb 17, 2026 — not a discretionary trade.
- Proceeds: ~$13,354.
- Shares owned after transaction: Not stated on the Form 4.
- Filing: Form 4 filed Feb 20, 2026 (appears timely within the required reporting window).
- Other: Exhibit 24.1 (Limited Power of Attorney) is attached per the filing.
Context This was a routine sell-to-cover tied to RSU vesting (tax withholding). Such sales are common and are administrative in nature rather than explicit signals of insider sentiment. The filing makes clear the sales were automatic and not a discretionary sale by the reporting person.
Insider Transaction Report
Form 4
Swartz Robin
COO & CBO
Transactions
- Sale
Common Stock
[F1][F2]2026-02-18$3.44/sh−3,882$13,354→ 206,196 total
Footnotes (2)
- [F1]Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2026. The sales do not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.47, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Signature
/s/ Gregory L. Shiferman, as Attorney-in-Fact for Robin Swartz|2026-02-20